Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106
View directory record Official record
Conditions
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
35 Years to 85 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
13
States / cities
Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease

NCT01864655
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
saracatinib, Placebo
Drug
Lead sponsor
Stephen M. Strittmatter
Other
Eligibility
50 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Results available

The Feasibility of Florbetapir Quantitation

NCT01946243
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Florbetapir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 28, 2026, 4:36 PM EDT
Recruiting No phase listed Observational

The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study

NCT00317616
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2037
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Not applicable Interventional

The Aging Brain ANSWERS Program

NCT03397667
View directory record Official record
Conditions
Traumatic Brain Injury, Alzheimer Disease, Veterans, Family Caregivers, Caregiver Burden, Quality of Life
Interventions
ABC ANSWERS, Control
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 90 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 28, 2026, 4:36 PM EDT
Completed No phase listed Observational Results available

Identifying Patients With Dementia in Primary Care

NCT00289471
View directory record Official record
Conditions
Dementia, Memory Disorders
Interventions
No intervention delivered.
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 28, 2026, 4:36 PM EDT
Recruiting No phase listed Observational

Cognitive and Vascular Functioning Following TBI

NCT06034509
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Decline, Vascular Dementia
Interventions
No intervention. This is an observational study.
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 74 Years
Enrollment
300 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 28, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.

NCT00938665
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
Interventions
COGNISION™ System
Device
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
7
States / cities
West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

Early Cognitive Intervention in Delirium

NCT04740567
View directory record Official record
Conditions
Delirium, Cognitive Decline, Dementia
Interventions
Cognitive Training, Goal Management Training
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 28, 2026, 4:36 PM EDT
Active, not recruiting No phase listed Observational

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma, Aggressive
Interventions
collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
12
States / cities
Miami, Florida • Rochester, Minnesota • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Exercise Trial for Alzheimer's Disease

NCT01311492
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Healthy Lifestyle Program, Physical Activity Intervention
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

NCT02534480
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
NGP 555
Drug
Lead sponsor
NeuroGenetic Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pilot Study of Minocycline in Huntington's Disease

NCT00277355
View directory record Official record
Conditions
Huntington Disease
Interventions
minocycline, Matching placebo
Drug
Lead sponsor
Merit Cudkowicz
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Birmingham, Alabama • Englewood, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Eudaimonia and Sleep: Effects of a Mindfulness Intervention in Caregivers of People With Dementia

NCT03857308
View directory record Official record
Conditions
Caregivers, Burnout, Sleep
Interventions
Mindfulness Training, Reappraisal Training
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

NCT04002674
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Placebo oral capsule, Nilotinib Oral Capsule
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

NCT00407576
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
[11C]MeS-IMPY
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

Treatment of Huntington's Chorea With Amantadine

NCT00001930
View directory record Official record
Conditions
Chorea, Huntington's Disease
Interventions
Amantadine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 4:36 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548
View directory record Official record
Conditions
Huntington's Disease
Interventions
20 mg BID of PF-02545920
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 66 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 28, 2026, 4:36 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

NCT03860935
View directory record Official record
Conditions
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions
acoramidis, Placebo Oral Tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 28, 2026, 4:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 28, 2026, 4:36 PM EDT